- Home
- SRG vs VANI Comparison
SRG vs VANI Comparison
Compare SRG & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRG | VANI |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.5M | 111.0M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SRG | VANI |
|---|---|---|
| Price | $1.58 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | ★ 135.0K | 122.7K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,204,000.00 | $4,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.30 | N/A |
| 52 Week Low | $1.55 | $0.92 |
| 52 Week High | $4.38 | $1.92 |
Technical Indicators
Market Signals| Indicator | SRG | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 34.21 | 34.71 |
| Support Level | $1.57 | $1.10 |
| Resistance Level | $2.08 | $1.25 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 14.52 | 12.72 |
Price Performance
Historical ComparisonAbout SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.